Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, taking advantage of the early data on offer from the country’s faster and more lightly regulated trials.
Large pharmaceutical groups including GSK, Merck and AstraZeneca have each signed $1bn-plus agreements in the past two years to buy the rights to develop and sell Chinese drugs outside the country.
Meanwhile, investors including Forbion, Bain Life Sciences and General Atlantic have ploughed hundreds of millions of dollars into new biotechs that will develop Chinese assets for western markets, hoping to be bought by major drugmakers.
您已阅读9%（662字），剩余91%（7022字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。